In vivo最新文献

{"title":"The Systemic Immune-inflammation Index (SII) Is an Independent Prognostic Factor for Patients With Recurrent Esophageal Cancer After Esophagectomy.","authors":"Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Sosuke Yamamoto, Keisuke Kazama, Kiyoko Shimada, Momoko Fukuda, Hideaki Suematsu, Haruhiko Cho, Miwha Ju, Natsumi Kamiya, Naoko Okuda, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.14031","DOIUrl":"10.21873/invivo.14031","url":null,"abstract":"<p><strong>Background/aim: </strong>The systemic immune-inflammation index (SII) has been developed and reported to be a useful prognostic factor in various malignancies. The aim of the present study was to evaluate the clinical impact of the SII as a prognostic factor for esophageal cancer recurrence after esophagectomy.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed the medical records and collected data from consecutive patients with recurrent EC who received any treatment after recurrence at Yokohama City University from 2005 to 2022.</p><p><strong>Results: </strong>Ninety-four patients were included in this study. The median age was 69 years. The study included 83 men and 11 women. The median overall survival (OS) was 11.2 months. According to previous studies and 1- and 3-year OS rates, we set the cutoff value of the SII at 500 in the present study. Ninety-four patients were divided into an SSI-low group (n=36) and an SSI-high group (n=58). The 1- and 3-year OS rates were 84.9% and 44.7%, respectively, in the SSI-low group and 28.8% and 13.1%, respectively, in the SSI-high group. There were significant differences between the two groups (<i>p</i><0.001). In the univariate and multivariate analyses, the SII was selected as an independent prognostic factor (hazard ratio=2.833, 95% confidence interval=1.555-5.161, <i>p</i><0.001). The rate of first-line treatment introduction was 86.1% (31/36) in the SII-low group and 63.8% (37/58) in the SII-high group (<i>p</i>=0.019). In addition, the patients did not continue first-line chemotherapy because of disease progression, which was marginally significantly higher in the SII-high group than in the SII-low group.</p><p><strong>Conclusion: </strong>The SII was an independent prognostic factor. In addition, the SII affects the clinical course of treatment after recurrence. Therefore, physicians might have a chance to make better decisions for treatment and management of recurrent EC using the SII.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2340-2348"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-analysis of Powered Circular Stapler <i>Versus</i> Manual Circular Stapler for Colorectal Anastomosis.","authors":"Hiroshi Ohtani, Masatsune Shibutani, Fukuoka Tatsunari, Hiroaki Kasashima, Kiyoshi Maeda","doi":"10.21873/invivo.14012","DOIUrl":"10.21873/invivo.14012","url":null,"abstract":"<p><strong>Background/aim: </strong>The anastomotic leakage rate of the double stapling technique anastomosis in colorectal surgery remains high at approximately 10%. The Echelon Circular™ powered stapler (ECPS) has been recently reported to reduce the risk of anastomotic leakage. A meta-analysis was conducted to evaluate and compare the effectiveness of ECPS to that of the manual circular stapler (MCS) in left-sided colorectal resections.</p><p><strong>Materials and methods: </strong>We searched publicly available literature databases for studies published between 2018 and August 2024. The following search terms were used: \"powered circular stapler\", \"powered circular\", \"anastomosis\", and \"powered echelon\". We analyzed several outcomes including anastomotic leakage, major anastomotic leakage, and anastomotic bleeding. A subgroup analysis was performed to analyze Japanese cases only.</p><p><strong>Results: </strong>We identified 9 papers reporting results that compared ECPS for left-sided colorectal resection with MCS. Our meta-analysis included 3,301 patients with colorectal anastomosis; 1,135 had undergone ECPS and 2,166 had undergone MCS. The overall anastomotic leakage rate was significantly lower in the ECPS group than in the MCS group (<i>p</i><0.0001). Regarding major anastomotic leakage, there was a tendency for the ECPS group to include fewer cases than the MCS group (<i>p</i>=0.10). For anastomotic bleeding, no significant difference was found between the two groups. In the subgroup analysis of Japanese patients, ECPS also showed significantly lesser anastomotic leakage than MCS.</p><p><strong>Conclusion: </strong>ECPS may significantly reduce the rate of anastomotic leakage in left-sided colorectal surgery compared to MCS in both the Western and Asian populations.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2165-2175"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Days of Antibiotic Spectrum Coverage to Quantify Antibiotic De-escalation: A Single-center Observational Study.","authors":"Ryo Hasui, Tomohiro Mizuno, Shintaro Nakao, Takako Yokoyama, Shigeki Yamada, Kazuo Takahashi, Kazuyoshi Nagashima","doi":"10.21873/invivo.14045","DOIUrl":"10.21873/invivo.14045","url":null,"abstract":"<p><strong>Background/aim: </strong>Effective monitoring of antibiotic use is essential for antimicrobial stewardship. While Days of Therapy (DOT) is commonly used to assess antibiotic consumption, it does not fully capture changes in antimicrobial spectrum during de-escalation. To address this, the Days of Antibiotic Spectrum Coverage (DASC) metric-calculated using a spectrum score weighted by antimicrobial breadth-was developed. This study aimed to evaluate the utility of DASC in identifying trends in antibiotic de-escalation across hospital wards and to determine whether it can serve as a reliable metric for assessing the appropriateness of antibiotic use at the departmental level.</p><p><strong>Patients and methods: </strong>This single-center retrospective study was conducted at an acute care community hospital in Japan, which has 21 clinical departments and 250 inpatient beds, including four intensive care unit beds. We retrospectively analyzed trends in inpatient antimicrobial use from May 2019 to March 2023 using DASC to assess the effectiveness of a newly instituted antimicrobial stewardship program.</p><p><strong>Results: </strong>DASC/DOT in the Otolaryngology and respiratory medicine wards showed a significant decreasing trend, but a significant increase was observed in both the surgery and general practice wards. We observed no significant trends in the other wards. In the surgery and respiratory medicine wards, broad-spectrum antimicrobials such as carbapenems were frequently used.</p><p><strong>Conclusion: </strong>DASC highlighted differences in the trends of antimicrobial de-escalation at the ward level and identified targets for antimicrobial stewardship intervention.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2449-2455"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vonoprazan-associated Microscopic Colitis and Continued Use After Onset: A Study Using a Japanese Pharmacovigilance Database.","authors":"Kota Nakanishi, Yuichi Uwai, Tomohiro Nabekura","doi":"10.21873/invivo.14034","DOIUrl":"10.21873/invivo.14034","url":null,"abstract":"<p><strong>Background/aim: </strong>Microscopic colitis is a known side-effect of proton pump inhibitors, but its association with the potassium-competitive acid blocker vonoprazan remains unclear. This study investigated this relationship, including the continued administration of vonoprazan after colitis onset.</p><p><strong>Patients and methods: </strong>Data from the first quarter of 2004 until the first quarter of 2024 in the Japanese Adverse Drug Event Report (JADER) database were analyzed. The reporting odds ratio (ROR) with its 95% confidence interval (CI) was calculated, and logistic regression analyses were performed. The proportion of patients with continued administration after onset was compared using Fisher's exact test with Bonferroni correction, and the administration duration was analyzed using the Steel-Dwass test.</p><p><strong>Results: </strong>Among 1,523,914 adverse drug event reports from 921,160 cases, 751 reports of microscopic colitis were identified. Lansoprazole was the suspected cause in 481 reports (ROR=362, 95% CI=311-421), whereas vonoprazan appeared in 55 reports (ROR=33.5, 95% CI=25.4-44.1). Univariate and multivariate analyses yielded adjusted ORs of 2.56 (95% CI=2.23-2.93) and 2.87 (95% CI=2.48-3.31), respectively, for the association between vonoprazan and microscopic colitis. The time to onset of microscopic colitis in vonoprazan users ranged from 7 to 731 days (median=31 days). The proportion of reports in which lansoprazole and vonoprazan were continued after microscopic colitis onset was higher than that of vonoprazan continuation after drug eruption (<i>i.e</i>. adverse cutaneous reactions). The duration of continued administration after microscopic colitis onset was longer than that after drug eruption.</p><p><strong>Conclusion: </strong>Using the JADER database, this study identified a safety signal for microscopic colitis associated with vonoprazan which is not listed in its package insert. Patients might continue vonoprazan after the onset of microscopic colitis. Although the database relies on spontaneous reporting, these findings warrant further investigation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2363-2370"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren's Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction.","authors":"Ying-Hsuan Tsai, Jeng-Wei Lu, Jou-I Tu, Yuan-Ju Li, Hui-Fu Hsu, Feng-Hao Chang, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.14018","DOIUrl":"10.21873/invivo.14018","url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) are chronic autoimmune diseases that often coexist. They share features such as systemic inflammation and multi-organ involvement and typically require long-term immunosuppressive treatment. However, long-term use of immunosuppressants can cause serious side effects, highlighting the need for adjunct therapies. Molecular hydrogen (H₂) therapy shows anti-inflammatory, antioxidant, and immunomodulatory properties, with potential benefits in liver, lung, and metabolic diseases. This case report examines a patient with overlapping SLE, SS, and interstitial lung disease (ILD), evaluating the effects of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function.</p><p><strong>Case report: </strong>We present the case of a 69-year-old female diagnosed with Sjögren's syndrome, SLE, and ILD. The patient exhibited chronic symptoms, including xerostomia, xerophthalmia, and respiratory distress, for which she had been receiving corticosteroids and immunomodulatory therapy. Given the persistent disease burden and concerns regarding long-term immunosuppressive therapy, molecular hydrogen therapy was introduced as an adjunctive treatment. Over several months, the patient experienced notable clinical improvements, including resolution of xerostomia, insomnia, dyspnea, chest pain, and dizziness. These symptomatic improvements correlated with favorable immunological shifts in T and B cell subsets, enhanced pulmonary imaging findings, and a reduction in inflammatory markers. Additionally, the patient reported a significant decrease in fatigue, allowing corticosteroid tapering and less reliance on nighttime oxygen. Ongoing hydrogen therapy with high-dose vitamin C maintained disease stability and improved quality of life.</p><p><strong>Conclusion: </strong>This case highlights the potential of molecular hydrogen (H₂) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H₂ therapy improved immune profiles and stabilized symptoms in a patient unresponsive to standard treatments.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2228-2235"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questionnaire Survey of Dual-energy Computed Tomography Utilization in Clinical Practice in Japan.","authors":"Shingo Ohira, Junji Mochizuki, Shunsuke Itaya, Tsukasa Kojima, Kazutaka Hoyoshi, Kazuyuki Endo, Nobuo Kitera, Daisuke Sakabe, Masanari Minamitani, Atsuto Katano, Keiichi Nakagawa","doi":"10.21873/invivo.14036","DOIUrl":"10.21873/invivo.14036","url":null,"abstract":"<p><strong>Background/aim: </strong>Dual-energy computed tomography (DECT) is an advanced imaging modality that enables material differentiation and enhanced diagnostic capabilities. This study aimed to investigate clinical DECT utilization in hospitals through a nationwide questionnaire survey.</p><p><strong>Patients and methods: </strong>An electronic questionnaire survey was sent to medical staff to investigate the use of DECT in clinical practice at each hospital in Japan. The questionnaire consisted of two parts: the first part asked for general information about the hospital, and the second asked for the detailed utilization of DECT in clinical practice.</p><p><strong>Results: </strong>A total of 231 responses were analyzed, among which 176 hospitals had 252 DECT scanners. Most DECTs (92.5%) were used in CT departments, while 6%, 1.2%, and 0.4% scanners were used in emergency, radiotherapy, and angiography departments, respectively. Without a contrast-enhanced agent (CEA), the examinations using DECT were mostly performed for the spine, extremities, and head regions, whereas with CEA they were performed for the chest, abdomen, and vasculature regions. The virtual monochromatic images (VMI) were most frequently reconstructed in clinical practice for both without (69.0%) and with (88.9%) CEA, and calcium and iodine density images were the next most used in examinations without CEA (22.6%) and with CEA (50.8%), respectively. The iodine reduction using low-keV VMI was performed in a 36% DECT scanner.</p><p><strong>Conclusion: </strong>The clinical utilization of DECT, including the type of DECT scanner, department of installation, scanned objects, and reconstructed images varied considerably across hospitals.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2377-2386"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.","authors":"Akinori Minato, Yui Mizushima, Yoshihiro Sugita, Tomohisa Takaba, Takuo Matsukawa, Kazumasa Jojima, Rieko Kimuro, Katsuyoshi Higashijima, Yujiro Nagata, Ikko Tomisaki, Eiji Kashiwagi, Naohiro Fujimoto","doi":"10.21873/invivo.14008","DOIUrl":"10.21873/invivo.14008","url":null,"abstract":"<p><strong>Background/aim: </strong>Avelumab maintenance therapy following first-line platinum-based chemotherapy is reportedly effective against advanced urothelial carcinoma (UC). However, this therapy, including its survival outcome, remains poorly investigated in a real-world setting in Japan.</p><p><strong>Patients and methods: </strong>This study retrospectively evaluated the clinical outcomes of avelumab maintenance therapy in patients with advanced lower- and upper-tract UC after no progression on first-line platinum-based chemotherapy at our institution between May 2021 and August 2024. Efficacy, survival, and safety analyses were performed starting from avelumab introduction.</p><p><strong>Results: </strong>In total, 22 patients were enrolled, of which 7 (31.8%) were female, 9 (40.9%) had performance status score ≥1, and 9 (40.9%) had upper-tract UC. The objective response and disease control rates were 4.5% and 50.0%, respectively. While receiving avelumab, no patients experienced immune-related adverse events (irAEs) of grade ≥3. The median progression-free survival (PFS) and overall survival were 3.3 and 22.2 months, respectively. When comparing median PFS of patients with a complete or partial response to prior platinum-based chemotherapy to the patients with stable disease, the first had significantly longer PFS (4.0 months, 95% confidence interval=2.3-10.1 <i>vs</i>. 2.2 months, 95% confidence interval=0.9-3.9; <i>p</i>=0.034). The PFS did not significantly differ between patients with and without irAEs or infusion-related reaction.</p><p><strong>Conclusion: </strong>Avelumab maintenance therapy demonstrated favorable survival outcomes and tolerability in patients with advanced UC in daily practice.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2123-2132"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Metformin Usage in Patients With Metastatic Colorectal Cancer Receiving First-line Systemic Therapy.","authors":"Efe Cem Erdat, Merih Yalciner, Yasemin Geris, Gungor Utkan","doi":"10.21873/invivo.14032","DOIUrl":"10.21873/invivo.14032","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the effect of metformin usage on progression-free (PFS) and overall (OS) survival in patients with metastatic colorectal cancer (mCRC) receiving first-line systemic therapy.</p><p><strong>Patients and methods: </strong>This was a single-center retrospective cohort study of patients aged 18 years or older with histologically confirmed mCRC receiving first-line systemic 5-fluorouracil-based chemotherapy combined with either anti-epidermal growth factor receptor (EGFR) therapy or anti-vascular endothelial growth factor (bevacizumab) between January 2010 and December 2022. This study examined the effect of metformin on PFS and OS of patients with mCRC.</p><p><strong>Results: </strong>A total of 134 patients were included, with a median age of 59.5 years; 66.4% of the patients were male, and 23.9% had diabetes. Metformin usage was associated with a significant improvement in median PFS (14.0 <i>vs</i>. 9.9 months, <i>p</i>=0.04) but not in median OS (20.7 <i>vs</i>. 19.5 months, <i>p</i>=0.76). In univariate Cox regression for PFS, metformin usage (hazard ratio=0.62, <i>p</i>=0.04) and anti-EGFR therapy (hazard ratio=0.54, <i>p</i><0.01) were associated with significantly lower hazard ratios.</p><p><strong>Conclusion: </strong>Metformin usage in patients with mCRC receiving systemic therapy may improve progression-free survival but does not significantly affect overall survival. This result outlines the potential of metformin in mCRC treatment, especially in enhancing the progression-free survival. Further studies are needed to confirm the role of metformin in systemic treatment of mCRC.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2349-2356"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JADER Database-based Analysis of the Association Between Tranexamic Acid and Thromboembolism and Related Risk Factors.","authors":"Natsuko Ishida, Toshihiro Shibata, Yukio Suga, Junko Ishizaki","doi":"10.21873/invivo.14025","DOIUrl":"10.21873/invivo.14025","url":null,"abstract":"<p><strong>Background/aim: </strong>Tranexamic acid (TXA) is widely used as a hemostatic agent and for various other indications, including dermatological and inflammatory conditions. However, its association with thromboembolism in the real-world setting remains unclear. In this study, we aimed to evaluate this association.</p><p><strong>Patients and methods: </strong>We collected data from the Japan Adverse Drug Event Report database from Q1 2004 to Q3 2020 and performed reporting odds ratio analyses and multivariate logistic regression analysis.</p><p><strong>Results: </strong>Overall, 1,735,923 reports were analyzed. TXA was the suspected causal drug in 54 cases of venous thromboembolism (VTE) and 8 cases of arterial thromboembolism. A significant signal was detected for VTE (reporting odds ratio=6.61; 95% confidence interval=5.03-8.70) but not for arterial thromboembolism. VTE cases involving TXA were more frequently reported in women and individuals with a body mass index of ≥25 than in other groups.</p><p><strong>Conclusion: </strong>TXA may be associated with VTE. The findings highlight the importance of careful patient monitoring during TXA administration, particularly in high-risk populations such as women and individuals who are overweight.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2295-2301"},"PeriodicalIF":1.8,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion Surgery Performed Following Durvalumab Combined With Gemcitabine and Cisplatin in Cholangiocarcinoma: A Case Report.","authors":"Yoshiyuki Tagayasu, Rin Yamada, Kosuke Kanemitsu, Yoshihiko Kondo, Rumi Itoyama, Hiromitsu Hayashi, Yoshihiro Komohara, Masaaki Iwatsuki","doi":"10.21873/invivo.13974","DOIUrl":"https://doi.org/10.21873/invivo.13974","url":null,"abstract":"<p><strong>Background/aim: </strong>Immunotherapy using immune checkpoint inhibitors (ICIs) has been widely approved for many cancers. ICI therapy has also been performed for unresectable bile duct cancer in recent years. However, there are few reports of conversion surgery following ICI therapy for unresectable or borderline resectable bile duct cancer. Herein, we present a case of conversion surgery following immune checkpoint ICI therapy for unresectable cholangiocarcinoma, focusing on the cancer immune microenvironment of this case.</p><p><strong>Case report: </strong>A 77-year-old man was diagnosed with borderline resectable, distal bile duct cancer and hilar cholangiocarcinoma. The patient underwent four courses of durvalumab combined with gemcitabine and cisplatin (Dur+GC) therapy. Evaluation of disease progression showed stable disease (SD), and considering the patient's surgical risk, a pancreaticoduodenectomy was performed. Adenocarcinoma components remained, and detailed pathological examinations using immunohistochemistry were performed. Marked infiltration of lymphocytes was observed in both the cancer core area and the margin area. The lymphocytes were positive for CD3 and CD8, with a subset also expressing CD103. PD-L1 expression was weakly positive in the stromal area, and positive cells were likely to be infiltrating macrophages in morphological features. Cancer cells were positive for HLA-A/B/C and beta-2.</p><p><strong>Conclusion: </strong>CD103+ CD8+ T cells, recently referred to as tissue-resident memory T cells, might be a critical immune cell population involved in ICI-induced anticancer immune responses in cholangiocarcinoma.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1724-1730"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}